VMD vs. CO, ACB, IVVD, SERA, LYRA, HCAT, SOPH, ENTA, NAUT, and AVIR
Should you be buying Viemed Healthcare stock or one of its competitors? The main competitors of Viemed Healthcare include Global Cord Blood (CO), Aurora Cannabis (ACB), Invivyd (IVVD), Sera Prognostics (SERA), Lyra Therapeutics (LYRA), Health Catalyst (HCAT), SOPHiA GENETICS (SOPH), Enanta Pharmaceuticals (ENTA), Nautilus Biotechnology (NAUT), and Atea Pharmaceuticals (AVIR). These companies are all part of the "medical" sector.
Viemed Healthcare (NASDAQ:VMD) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.
Viemed Healthcare has a net margin of 5.60% compared to Global Cord Blood's net margin of 0.00%. Viemed Healthcare's return on equity of 9.59% beat Global Cord Blood's return on equity.
Global Cord Blood has higher revenue and earnings than Viemed Healthcare. Global Cord Blood is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.
Viemed Healthcare has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
Global Cord Blood received 336 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 74.29% of users gave Global Cord Blood an outperform vote while only 33.33% of users gave Viemed Healthcare an outperform vote.
In the previous week, Global Cord Blood had 2 more articles in the media than Viemed Healthcare. MarketBeat recorded 3 mentions for Global Cord Blood and 1 mentions for Viemed Healthcare. Global Cord Blood's average media sentiment score of 0.02 beat Viemed Healthcare's score of 0.00 indicating that Global Cord Blood is being referred to more favorably in the news media.
74.2% of Viemed Healthcare shares are held by institutional investors. 19.2% of Viemed Healthcare shares are held by company insiders. Comparatively, 0.5% of Global Cord Blood shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Viemed Healthcare beats Global Cord Blood on 8 of the 15 factors compared between the two stocks.
Get Viemed Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viemed Healthcare Competitors List
Related Companies and Tools
